News from CLS - Interview with and research by Dr Eric Walser University of Texas Medical Branch

Dr Eric Walser is an internationally recognized interventional radiologist with extensive clinical experience of using non-surgical ablation for the treatment of small tumors as an alternative to traditional surgery. Dr Eric Walser uses the TRANBERG® Thermal Therapy System to treat localized prostate cancer in clinical practice.

"As laser ablation is associated with low risk and high precision, I see significant potential for this method of treatment in prostate cancer", says Dr Eric Walser in our interview with him. Read the full interview and become acquainted with his research on laser ablation on our website Interview with and research by Dr Eric Walser University of Texas Medical Branch - CLS (clinicallaser.se), or in the attached pdf provided below.

Contact Information:

Liselotte Nilsson, VP Marketing, Clinical Laserthermia Systems AB (publ)

Phone: +46 – (0)703 – 73 64 43 E-mail: lotta.nilsson@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: www.clinicallaser.com .